8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 26, 2026·SEC
Insight Molecular Diagnostics Inc.(IMDX)Earnings, Financials & Key Ratios
IMDX•NASDAQ
$5.40
Price updated Jun 27, 2026
AboutOncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Show more
- Revenue$4M+115.6%
- EBITDA-$28M+52.3%
- Net Income-$50M+17.2%
- EPS (Diluted)-1.65+64.6%
- Gross Margin4.69%-88.1%
- EBITDA Margin-699.9%+77.9%
- Operating Margin-754.08%+76.8%
- Net Margin-1238.52%+61.6%
IMDX Price & Volume
Insight Molecular Diagnostics Inc. (IMDX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Long-term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall
"Insight Molecular Diagnostics faces a precarious outlook as its DetermaRx assay fails to achieve consistent market penetration, evidenced by a 98.5% revenue decline in 2026Q1. The company's inability to align operating expenses with top-line growth has resulted in a negative equity position of $10.7 million, raising significant concerns regarding its long-term viability. Investors should monitor the company's ability to secure non-dilutive capital, as the current cash burn rate and lack of positive free cash flow suggest an imminent liquidity shortfall."
Verdict Logic
the company's inability to achieve commercial scale is highlighted by a 2026Q1 gross margin of -18.9% and a total absence of positive free cash flow over the last ten quarters.
IMDX Growth Metrics
Insight Molecular Diagnostics Inc. (IMDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years27.24%
3 Years61.76%
TTM-49.28%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM17.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM57.08%
Return on Capital
10 Years-122.21%
5 Years-75.79%
3 Years-102.51%
Last Year-147.41%
IMDX Recent Earnings
Insight Molecular Diagnostics Inc. (IMDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 7/12 qtrs (64%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.28-7.1%
$0.26
Rev
$32,000-86.0%
$229,225
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.27-13.7%
$0.24
Rev
$1M+299.6%
$285,000
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.34-41.7%
$0.24
Rev
$260,000-8.8%
$285,000
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.30-30.4%
$0.23
Rev
$518,000+72.7%
$300,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.28vs $0.26-7.1% | $32,000vs $229,225-86.0% |
| Q2 2026 | Mar 26, 2026 | $0.27vs $0.24-13.7% | $1Mvs $285,000+299.6% |
| Q4 2025 | Nov 10, 2025 | $0.34vs $0.24-41.7% | $260,000vs $285,000-8.8% |
| Q3 2025 | Aug 11, 2025 | $0.30vs $0.23-30.4% | $518,000vs $300,000+72.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Insight Molecular Diagnostics Inc. (IMDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.40 | $144.94M | -3.27 | 115.58% | -1238.52% | — | — | |
| $261.91 | $37.51B | -172.31 | 35.9% | -9.05% | -15.13% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $28.82 | $1.49B | -72.05 | 13.79% | -1.98% | -2.61% | — | |
| $176.55 | $26.82B | 32.39 | -0.78% | 19.43% | 32.84% | — | |
| $1.65 | $512.49M | -0.91 | 3.89% | -80.34% | -488.45% | — |
Compare IMDX vs Peers
Insight Molecular Diagnostics Inc. (IMDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMDX SEC Filings & Documents
Insight Molecular Diagnostics Inc. (IMDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IMDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMDX Frequently Asked Questions
Insight Molecular Diagnostics Inc. (IMDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Insight Molecular Diagnostics Inc.'s revenue?
Insight Molecular Diagnostics Inc. (IMDX) reported $1.9M in revenue for fiscal year 2025.
How fast is Insight Molecular Diagnostics Inc. growing?
Insight Molecular Diagnostics Inc. (IMDX) grew revenue by 115.6% over the past year. This is strong growth.
Is IMDX profitable?
Insight Molecular Diagnostics Inc. (IMDX) reported a net loss of $47.8M for fiscal year 2025.
Dividend & Returns
What is Insight Molecular Diagnostics Inc.'s free cash flow?
Insight Molecular Diagnostics Inc. (IMDX) had negative free cash flow of $27.5M in fiscal year 2025, likely due to heavy capital investments.